How a tetrapeptide gained the strongest clinical evidence base of any longevity peptide—and why the FDA still said no.

SS-31 is a tetrapeptide that has the distinction of being the longest-studied peptide in the modern longevity cluster. Unlike most compounds in this space, it has advanced through Phase III clinical trials, generated substantial peer-reviewed evidence, and triggered FDA review. Yet it remains unlicensed and unavailable through standard medical channels. This paradox—maximum clinical rigor combined with regulatory rejection—is instructive. It shows that biological activity and trial data do not automatically convert to approved medicine. It also demonstrates the genuine challenge of designing clinical endpoints for rare mitochondrial diseases.

SS-31, sold previously under the brand name Bendavia and developed as MTP-131 by Hazel Szeto’s laboratory at Weill Cornell, works by stabilizing the inner mitochondrial membrane. It does not scavenge free radicals. Instead, it prevents aberrant reactive oxygen species generation at the sites where electrons leak from the energy chain. For certain rare genetic mitochondrial disorders—Barth syndrome, primary mitochondrial myopathy—this mechanism addresses a root cause. For the broader population, the promise is more speculative. This article takes an honest, evidence-first view: the clinical data is real, the gaps are real, and the regulatory rejection is explicable even if not inevitable.

We will examine the mechanism in detail, survey the human evidence, address the gap between preclinical hope and clinical outcome, and situate SS-31 within the larger landscape of longevity pharmacology. If you are considering SS-31 for any purpose, you should read this article in full and discuss the evidence with a physician who understands both mitochondrial biology and the specific disease or condition you are addressing.

Quick Facts

↑ Back to contents

What Is SS-31?

SS-31 is a synthetic four-amino-acid peptide designed to penetrate the inner mitochondrial membrane and bind to cardiolipin, a signature phospholipid of that compartment. Its chemical designation is D-Arg-Dmt-Lys-Phe-NH2. The “Dmt” moiety is 2′,6′-dimethyltyrosine, a modified amino acid that increases lipophilicity and allows the peptide to cross the lipid bilayer. Its molecular weight is approximately 640 daltons—small enough to be administered by injection, yet large enough to be relatively specific in its cellular targeting.

The “SS” in SS-31 honors Hazel Szeto and Solomon Snyder, who developed this peptide at Johns Hopkins and later Weill Cornell. It is now also known by the International Nonproprietary Name (INN) elamipretide, and was previously marketed as Bendavia by the company Stealth BioTherapeutics (now closed operations).

What distinguishes SS-31 from other peptides in the longevity cluster is its specificity and evidence base. It does not broadly enhance protein synthesis or growth signaling. It does not mimic growth hormone or insulin. Instead, it addresses a discrete molecular target—the architecture of the inner mitochondrial membrane—and has generated clinical-stage human data that most longevity peptides have not yet achieved.

↑ Back to contents

Origins and Discovery

SS-31 emerged from fundamental mitochondrial biology, not from a drug development pipeline aimed at aging. In the 1990s and 2000s, Hazel Szeto’s research group at Johns Hopkins (later at Weill Cornell) was investigating how cardiolipin—a phospholipid found almost exclusively in the inner mitochondrial membrane—was regulated and how its loss or damage contributed to cellular dysfunction.

Cardiolipin is not an incidental component. It is essential for the assembly and function of the electron transport chain. It anchors Complex I and Complex III, ensures efficient electron transfer, and stabilizes the architecture of the inner membrane folds (cristae). When cardiolipin is lost or damaged, the electron transport chain becomes leaky. Electrons escape without doing work, forming excess free radicals (reactive oxygen species, or ROS) and depleting the cell’s energy reserves.

This observation led to a hypothesis: if one could stabilize cardiolipin—essentially “hold the membrane together” at the molecular level—one might prevent the cascade of mitochondrial dysfunction that accompanies aging and certain genetic diseases.

The first SS-peptides were screened in cell culture. The “S” analogues (SS-1, SS-2, SS-3, etc.) were tested for their ability to bind to cardiolipin and preserve mitochondrial function during stress. SS-31 emerged as a lead candidate because it achieved high binding affinity, good penetration across the outer mitochondrial membrane, and robust protection against oxidative stress in multiple cell types.

Szeto’s team published the initial proof-of-concept studies in peer-reviewed journals between 2002 and 2009. The compounds gained attention because they worked in multiple disease models—cardiac ischemia, renal dysfunction, neurodegeneration—and did so without broad anti-inflammatory or antioxidant pharmacology. The mechanism was specific and anatomically targeted.

This specificity attracted pharmaceutical interest. Stealth BioTherapeutics licensed SS-31 (which they called MTP-131 in preclinical work) and carried it into human trials. The company conducted Phase I dose-escalation studies, followed by Phase II trials in specific indications, and ultimately Phase III trials in Barth syndrome and primary mitochondrial myopathy.

↑ Back to contents

Mechanism of Action

Understanding SS-31’s mechanism is crucial because it clarifies both why it works in certain contexts and why it does not work as broadly as one might hope.

The problem it addresses: When the electron transport chain is damaged or becomes inefficient—whether due to genetic mutation, aging, ischemia, or toxin exposure—electrons leak at multiple points. These leaked electrons react with molecular oxygen to form superoxide anion (O₂•⁻) and other reactive oxygen species. This excessive ROS does not serve as a beneficial signal. Instead, it damages proteins, lipids, and DNA, perpetuating mitochondrial decline and triggering cell death.

Cardiolipin as the target: SS-31 crosses both the outer and inner mitochondrial membranes (its D-Arg and Dmt residues make it membrane-permeable) and binds to cardiolipin on the inner surface of the inner membrane. Cardiolipin’s geometry—four phosphate groups arranged in space—allows multiple electrostatic and hydrophobic interactions with SS-31. This binding is not a loose association; it is a defined, measurable interaction that can be mapped using crystallography and spectroscopy.

Stabilization of cristae architecture: Cardiolipin is essential for maintaining the tight, parallel folds of the inner membrane called cristae. These folds maximize surface area and ensure close proximity between electron transport chain complexes. When cardiolipin is damaged or depleted, the cristae collapse. The complexes become spatially disorganized, electron transfer becomes inefficient, and leak points proliferate.

By binding to cardiolipin and, in effect, “holding the membrane together,” SS-31 restores and maintains the cristae structure even under stress. This stabilization is the key to its mechanism. Once the architecture is preserved, the electron transport chain functions more efficiently, electrons transfer more directly through the chain, and aberrant ROS production is reduced.

What SS-31 does NOT do: It does not scavenge free radicals like vitamin C or glutathione. It does not block ROS-generating enzymes. It does not have broad antioxidant activity. Instead, it prevents ROS from being generated in the first place—a more elegant but also more specific approach. This distinction matters: if ROS signaling is important for some cellular processes (and it is), then global ROS scavenging can have off-target effects. SS-31 avoids this problem by operating upstream, at the level of electron transfer itself.

Specificity and limitations: Because SS-31’s mechanism depends on stable, organized mitochondrial structure and active electron transport, it is most effective in tissues with high metabolic demands and intact mitochondrial architecture. It is less likely to work in cells whose mitochondria are severely fragmented or in disease states where the primary problem is not electron leak but, say, impaired ATP synthase or total loss of mitochondrial DNA.

In healthy individuals, mitochondria are already relatively efficient. SS-31 may reduce baseline ROS a modest amount, but it is unlikely to produce dramatic effects on aging or general health—unless those individuals have a hidden mitochondrial defect or are undergoing sustained stress (intense exercise, radiation, etc.). This is why SS-31 has been studied mostly in disease populations, not in healthy people.

↑ Back to contents

Key Research Areas and Studies

Preclinical and cell-based research: Szeto’s group and collaborators demonstrated SS-31 efficacy in cultured cardiomyocytes, neurons, renal tubule cells, and fibroblasts exposed to oxidative stress, ischemia-reperfusion injury, and mitochondrial toxins. These studies established proof-of-concept and guided dose ranges for later human work. Key papers appeared in Journal of the American College of Cardiology, Circulation, and American Journal of Physiology between 2008 and 2014.

Animal models: SS-31 improved outcomes in rodent models of acute myocardial infarction, stroke, acute kidney injury, and inherited mitochondrial disease. In a landmark study, SS-31 extended lifespan and improved metabolic health in a mouse model of mitochondrial myopathy caused by a mutation in the ANT1 gene. These animal data were compelling but, as always, did not automatically predict human efficacy.

Phase I (dose escalation, safety): Stealth BioTherapeutics conducted Phase I studies with healthy volunteers and with patients with specific diagnoses. The studies established tolerability up to 2.0 mg/kg IV and identified a pharmacologically active dose range. No major safety signals emerged.

Phase II trials: Early Phase II studies in acute heart failure (EMBRACE trial), renal ischemia-reperfusion injury (transplant recipients), and mitochondrial myopathy showed biological signals. Some patients improved in exercise capacity, some showed improvement in cardiac function measured by echocardiography. However, the trials were small and many endpoints did not reach statistical significance.

Phase III—the pivotal trials and regulatory turning point:

Barth syndrome (TAZPOWER trial): Barth syndrome is a rare X-linked disorder caused by mutations in the TAFAZZIN gene, which encodes an enzyme essential for cardiolipin remodeling. Patients present with dilated cardiomyopathy, skeletal muscle weakness, neutropenia, and recurrent infections. The primary endpoint of the TAZPOWER trial was a change in the 6-minute walk test (6MWT)—a measure of exercise capacity. The trial enrolled approximately 60 patients and ran over several months.

The results, announced in 2022 and later published, showed that SS-31 did not meet the primary endpoint: 6MWT distance did not improve significantly more with SS-31 than with placebo. However, secondary endpoints told a different story. Stroke volume improved more in the SS-31 group. Heart failure biomarkers (NT-proBNP) showed favorable trends. Exercise tolerance and dyspnea scores improved in subgroups. The biological activity was evident—the drug was working—but the chosen primary endpoint did not capture it.

The FDA subsequently rejected Stealth’s New Drug Application (NDA) in 2023, citing the failure to meet the primary endpoint. The agency did not question safety or mechanism; they questioned clinical meaningfulness of the non-primary endpoints. This is a critical juncture in the SS-31 story: a compound with genuine biological activity and some clinical benefit failed to clear the regulatory hurdle because the primary endpoint was not met.

Primary mitochondrial myopathy (MMPOWER trials): Two Phase III trials (MMPOWER-1 and MMPOWER-2) enrolled patients with genetically confirmed primary mitochondrial myopathy. Primary endpoints included measures of muscle strength and exercise capacity. These trials also failed to meet their primary endpoints, though some secondary measures and subgroup analyses suggested benefit. Again, Stealth faced the same regulatory dynamic: clear biological activity but insufficient change in the pre-specified primary outcome.

↑ Back to contents

Common Claims versus Current Evidence

↑ Back to contents

The Human Evidence Landscape

SS-31 is unique among longevity peptides in that it has human efficacy data. This is both a strength and a source of complexity.

What the clinical trials showed:

• In Barth syndrome patients, SS-31 improved stroke volume (a measure of heart pumping efficiency) compared to placebo. This is a genuine biological effect on the target tissue.
• Exercise tolerance improved in some measures and some subgroups, though not uniformly across all trial participants or all measures.
• Biomarkers of heart failure (NT-proBNP, a natriuretic peptide released when the heart is stressed) trended favorably with SS-31, suggesting reduced cardiac strain.
• No unexpected safety signals emerged. Adverse events were comparable between SS-31 and placebo groups.
• In primary mitochondrial myopathy, some patients reported subjective improvement in fatigue and exercise capacity; objective measures of muscle strength showed mixed results.

The regulatory problem: The FDA’s rejection was not arbitrary. The agency asked: “Does stroke volume improvement, in the absence of a change in 6-minute walk distance, constitute clinically meaningful benefit?” This is a legitimate question. Stroke volume is a physiological parameter; the 6-minute walk is what patients care about—whether they can walk farther and feel less limited.

The answer—a disagreement between the company and the FDA—illustrates a fundamental challenge in rare disease development. In Barth syndrome, there are perhaps 300–400 diagnosed patients in the United States. Running a large, definitive trial is difficult. Should the FDA accept a physiologically meaningful improvement (stroke volume) as a surrogate for clinical benefit, or insist on a directly patient-relevant measure even if the trial is underpowered for that measure? There is no universally correct answer, but the FDA’s conservatism is understandable given the limited patient population.

Quality of evidence: The Phase III trials were well-designed, double-blinded, and placebo-controlled. This is gold-standard evidence. However, the trials were conducted in rare disease populations, not in healthy people or in common conditions. Extrapolating to other populations is not straightforward.

Absence of evidence in healthy people: No formal clinical trial has examined SS-31 in healthy adults. There are no data on its effects on aging, longevity, exercise performance, or biomarkers of aging in the general population. Any claims about SS-31 for “anti-aging” or “general health” in healthy individuals rest entirely on mechanistic reasoning and animal data, not human evidence.

↑ Back to contents

Safety, Risks, and Limitations

Observed safety in clinical trials: Across Phase I, II, and III trials, SS-31 was well tolerated. Injection site reactions (redness, mild pain) were the most common adverse event with subcutaneous dosing. No serious organ toxicity, allergic reactions, or unexpected systemic effects were reported. This is a positive signal.

Mechanistic safety considerations:

• ROS reduction: Because SS-31 reduces ROS generation, a theoretical concern is that it might blunt beneficial ROS signaling. ROS participates in innate immune responses, mitochondrial biogenesis signaling (through AMPK and other pathways), and exercise adaptation. If SS-31 is too aggressive in lowering ROS, it might impair these adaptive responses. In the clinical trials, immune function was not severely compromised, but no specific measures of ROS-dependent signaling (e.g., AMPK activation, mitochondrial biogenesis markers) were reported.
• Off-target binding: SS-31 is designed to be specific for cardiolipin, but cardiolipin is found in other tissues besides the heart and skeletal muscle—notably, the brain, kidney, and liver. These tissues also express cardiolipin on their inner mitochondrial membranes. This is not necessarily a problem—stabilizing mitochondrial structure in these tissues could be beneficial—but it does mean that SS-31’s effects are not limited to the intended target organ. Long-term effects on these organs are largely unknown.
• Membrane interactions: At high concentrations, some amphipathic peptides can interact nonspecifically with cell membranes. The clinical doses used—5–40 mg SC daily in self-research, or 0.5–2.0 mg/kg IV in trials—are unlikely to produce this effect, but chronic dosing or higher doses are unexplored.

Practical risks:

• Injection complications: Subcutaneous injection carries risks of infection, abscess formation (especially with repeated daily injections), and local tissue damage if sterile technique is not maintained or if the solution is contaminated.
• Product quality: SS-31 is not commercially available through regulated channels. Any SS-31 obtained outside of a clinical trial is unregulated. Purity, identity, and sterility cannot be guaranteed. Underground peptide suppliers have variable quality control.
• Drug interactions: No formal drug-drug interaction studies have been conducted. If you are taking other medications, especially those affecting mitochondrial function (certain statins, antiretrovirals) or ROS signaling, interactions are possible but unstudied.
• Contraindications: There are no absolute contraindications identified, but SS-31 is not recommended in pregnancy (no safety data) and should be avoided by anyone with acute infection or immunosuppression until more is known.

Long-term safety: The longest human exposure to SS-31 in the published literature is approximately 12–16 weeks (the duration of Phase III trials). Safety beyond this window is essentially unknown. If anyone plans to use SS-31 long-term, they are in uncharted territory.

Efficacy ceiling: A crucial limitation is that SS-31’s benefit plateau is unknown. In the animal models and clinical trials, it improved but did not cure disease. It is not an anti-aging panacea; it is a mitochondrial stabilizer with modest effects in some contexts and negligible effects in others.

↑ Back to contents

Legal and Regulatory Status

FDA status: SS-31 (elamipretide) is a non-approved new drug. Its Investigational New Drug (IND) application was active, and three Phase III trials were conducted under FDA oversight. However, the New Drug Application (NDA) submitted by Stealth BioTherapeutics was rejected in 2023. The FDA did not cite safety concerns; the rejection was based on efficacy—specifically, the failure to meet pre-specified primary endpoints in the pivotal trials.

After an NDA rejection, a company can request a meeting with the FDA to discuss the path forward, submit additional data, or reapply. As of early 2026, Stealth BioTherapeutics (or its successors) has not announced plans to resubmit. The company’s financial situation and strategic priorities remain unclear publicly.

Other jurisdictions: The EMA (European Medicines Agency) and other regulatory bodies have not issued marketing authorizations for SS-31. In some countries with more lenient regulatory frameworks, compounds similar to SS-31 might be available as compounded medications or under compassionate use programs, but this is limited and not widespread.

Clinical trial access: If SS-31 remains under investigational status, it is theoretically available to enrolled patients in clinical trials through an Expanded Access Program or Compassionate Use pathway. However, with the NDA rejected and no active trials announced, this avenue may not be available. Interested patients should contact a medical center with mitochondrial disease expertise and inquire about ongoing trials or compassionate use options.

WADA and sports: SS-31 is not on the World Anti-Doping Agency’s Prohibited List of specific substances. However, because it is an unapproved drug, it would fall under S0 (non-approved substances), which are banned in competition. Any athlete considering SS-31 should understand that it is prohibited in sanctioned sports.

State and local regulations: In the United States, state medical boards regulate the practice of medicine. A physician cannot legally prescribe an unapproved drug except under a research protocol or, rarely, under Expanded Access procedures. Telemedicine clinics or compounding pharmacies claiming to offer SS-31 are operating in a legal gray zone. Patients should be aware of this legal ambiguity.

↑ Back to contents

Research Protocols and Laboratory Practices

Standard research dosing and administration: In published trials, SS-31 was administered via intravenous infusion at doses of 0.5–2.0 mg/kg, given once daily or multiple times per week. The infusion was slow (over 1–2 hours) to minimize local reactions. Alternatively, subcutaneous injection of 5–40 mg daily was used in some protocols, particularly in studies designed for outpatient or home administration.

Pharmacokinetics: SS-31 is a small peptide, and like all peptides, it is susceptible to degradation by proteases. Its plasma half-life is short—estimated at 20–30 minutes based on animal data—which is why frequent dosing is necessary. It distributes rapidly to tissues, particularly those with high metabolic rate and intact mitochondria. Brain penetration is limited by the blood-brain barrier, though some SS peptides have been designed with enhanced CNS penetration.

Stability and storage: SS-31 is typically supplied as a lyophilized (freeze-dried) powder that must be reconstituted with sterile water or saline immediately before use. Once reconstituted, it is unstable and should be used within hours. It should be stored at 2–8°C (35–46°F) in lyophilized form and not exposed to light or repeated freeze-thaw cycles.

Measurement and verification: In rigorous research settings, identity and purity of SS-31 are confirmed using high-performance liquid chromatography (HPLC) and mass spectrometry. These techniques separate and identify the peptide based on its chemical properties and molecular weight. For anyone considering SS-31 from a non-clinical source, these verification methods are not accessible; you have no way to confirm that what you have is actually SS-31.

Preclinical assays: Researchers use several assays to confirm SS-31’s activity: cardiolipin binding assays (measuring affinity using surface plasmon resonance or fluorescence titration); ROS detection (using fluorescent probes like DCFDA or MitoSOX in cells); and mitochondrial bioenergetics (measuring oxygen consumption and ATP production using Seahorse analyzers). These assays require specialized equipment and expertise.

Cell culture and animal models: SS-31 has been tested in numerous in vitro systems: isolated rat cardiac myocytes, human fibroblasts, neurons from various species, and renal proximal tubule cells. In vivo, it has been studied in aged mice, transgenic mice with mitochondrial mutations, and rodent models of acute injury. These models are useful for mechanism elucidation but do not directly predict human efficacy.

↑ Back to contents

Dosing in Published Research

Dose-response and optimization: The optimal dose and frequency for different indications remain incompletely characterized. The 0.5 mg/kg daily dose used in Phase III represents a practical compromise between efficacy and tolerability, but it was not derived from dose-response optimization studies. Higher doses might be more effective but could increase adverse events; lower doses might reduce side effects at the cost of efficacy.

Intravenous versus subcutaneous: IV administration achieves rapid, complete bioavailability but is logistically demanding and unsuitable for long-term outpatient use. Subcutaneous administration is more practical for chronic use but may have lower and more variable bioavailability due to degradation at the injection site. Comparative efficacy studies between routes are limited.

↑ Back to contents

Dosing in Independent Self-Experimentation Communities

Important caveats on self-experimentation dosing:

• No established safe or effective dose for healthy people: The doses listed above are inferred from animal studies and clinical trial doses, with no direct evidence that they are safe or effective in healthy individuals. They represent educated guesses.
• Unknown product identity: SS-31 obtained outside of regulated clinical trials has not been verified. It may be inert, contaminated, or misidentified. You have no assurance of what you are actually injecting.
• Sterility and safety: Non-clinical injections carry the risk of infection, abscess, and tissue damage if technique is compromised or if the product is not sterile.
• Lack of medical supervision: Unlike clinical trial participants, self-experimenters are not monitored for adverse events or biomarker changes. A serious complication could go unrecognized.
• Legal status: Self-administration of a non-approved drug is not illegal in most jurisdictions, but it is not prescribed or supervised by a licensed physician and therefore falls outside the framework of legitimate medical practice.

↑ Back to contents

Frequently Asked Questions

Q: Can I buy SS-31 right now?

A: Not legally through standard pharmaceutical channels. Stealth BioTherapeutics no longer operates. No company currently holds a license to manufacture or distribute SS-31 in the U.S. Underground peptide suppliers claim to offer it, but their products are unregulated and unverified. If you pursue this route, you are assuming substantial risk.

Q: Is SS-31 the same as Bendavia?

A: Yes. Bendavia was the brand name used by Stealth BioTherapeutics for SS-31 (elamipretide). MTP-131 was the preclinical designation. These refer to the same compound. Some suppliers may use these names interchangeably to evade detection or to appear more official.

Q: Will SS-31 help me if I have a mitochondrial disease?

A: Possibly, if you have Barth syndrome or primary mitochondrial myopathy and can access it through a clinical trial or compassionate use pathway. The evidence shows biological activity in these populations, though clinical benefit is modest and not guaranteed. For other mitochondrial disorders, evidence is sparse. Consult a mitochondrial disease specialist before considering SS-31.

Q: Will SS-31 help me if I’m healthy?

A: Unknown. No human study has examined this. In animal models of aging, SS-31 improved mitochondrial function and some longevity markers. This does not mean it will extend lifespan or improve health in healthy humans. The gap between preclinical and clinical efficacy is real and often large.

Q: Is SS-31 an amino acid? Is it a “natural” peptide?

A: SS-31 is a synthetic peptide. One of its four amino acids, Dmt (2′,6′-dimethyltyrosine), does not occur naturally in the human body. It is an engineered modification designed to increase membrane penetration. So no, SS-31 is not “natural,” though it is not toxic or alien to the body.

Q: What’s the difference between SS-31 and other mitochondrial peptides?

A: See Section 17 (“Related Peptides”). In brief, SS-31 is mechanism-specific (targets cardiolipin) and has the most clinical evidence. Other peptides in this space (e.g., humanin, SIRT-activating peptides) have different mechanisms and less or no human efficacy data.

Q: Does SS-31 have any drug interactions?

A: Formal drug-drug interaction studies have not been conducted. If you take medications that affect mitochondrial function—certain statins, some antiretrovirals, chemotherapy agents—interactions are theoretically possible. Discuss with a physician knowledgeable in both pharmacology and mitochondrial biology before combining SS-31 with other drugs.

Q: How long does SS-31 stay in my body?

A: The plasma half-life is estimated at 20–30 minutes. It is cleared relatively rapidly from circulation. However, it penetrates mitochondria and may persist in tissues longer than it persists in the blood. Complete pharmacokinetics in humans have not been fully characterized.

Q: Can I take SS-31 if I’m pregnant?

A: No. No safety data exist in pregnancy. Animal teratogenicity studies have not been published. SS-31 should be avoided in pregnancy and during breastfeeding.

Q: Will SS-31 show up on a drug test?

A: Standard drug tests (urine or blood for common substances) will not detect SS-31. If you are subject to WADA or other sports testing, note that SS-31 is prohibited (as a non-approved substance). A specialized test capable of detecting peptides could identify it, but routine screening would not.

↑ Back to contents

Related Peptides: How SS-31 Compares

SS-peptides (SS-02, SS-20, SS-31, SS-72): These are Szeto’s family of mitochondrial peptides. They all target cardiolipin but differ in potency, selectivity, and tissue penetration. SS-31 was chosen as the lead candidate because it balanced efficacy and tolerability. SS-02 is less lipophilic and does not cross membranes as well. SS-72 was designed for improved CNS penetration. Only SS-31 has advanced to Phase III trials.

Humanin: A 24-amino-acid peptide derived from mitochondrial DNA that has anti-apoptotic and metabolic effects. It has shown promise in Alzheimer’s disease models and age-related metabolic dysfunction. However, humanin has not advanced as far clinically as SS-31; most data are preclinical or in small Phase I/II trials. The mechanism is distinct (anti-apoptotic and insulin signaling) rather than membrane-stabilizing.

Urolithin A (not a peptide, but related mechanistically): A postbiotic compound that activates mitophagy—the selective autophagy of damaged mitochondria. It works at a different level than SS-31: rather than stabilizing existing mitochondria, it promotes the elimination of severely damaged ones and their replacement. Urolithin A is available as a supplement and has some human evidence in muscle health. It is a complement to SS-31 conceptually but not a substitute.

NAD+ boosters (NMN, NR): These compounds increase NAD+, a coenzyme essential for mitochondrial function and signaling. They work upstream of SS-31 conceptually. Some evidence in humans for metabolic benefits in metabolic syndrome. More established in the market than SS-31. Different mechanism and different evidence tier.

CoQ10 / Ubiquinol: A lipophilic antioxidant essential for electron transport. Unlike SS-31, CoQ10 directly participates in the electron transport chain. It can serve as an electron shuttle between complexes. It is well-studied and available over-the-counter. For mitochondrial dysfunction due to CoQ10 deficiency specifically, it is more directly relevant than SS-31. However, most aging is not due to CoQ10 deficiency.

Comparison summary: SS-31 is unique in its combination of specificity (targets cardiolipin), mechanism (membrane stabilization, not ROS scavenging or CoQ10 replacement), and clinical evidence (Phase III trials). Humanin and NAD+ boosters have some clinical data but have not advanced as far. Mitophagy activators and classical mitochondrial supplements (CoQ10) address different aspects of mitochondrial health. No single compound is a cure-all; a comprehensive approach to mitochondrial health might incorporate elements of multiple strategies.

↑ Back to contents

Summary and Key Takeaways

• Mechanism is real and specific: SS-31 binds to cardiolipin and stabilizes the inner mitochondrial membrane. This is not speculative; it has been demonstrated in cell-free assays, cultured cells, and animal tissues. The mechanism is elegant and mechanistically sound.
• Clinical evidence is the strongest in its class: SS-31 is the only longevity-associated compound to advance to Phase III clinical trials. This is a genuine distinction and reflects years of rigorous development.
• Clinical benefit is real but modest: In Barth syndrome and primary mitochondrial myopathy, SS-31 showed biological activity (improved stroke volume, improved biomarkers) but did not meet the primary endpoints chosen for the pivotal trials. Whether the drug “works” depends on which endpoint you ask about—a genuine interpretive challenge.
• The FDA rejection is understandable: The FDA did not reject SS-31 on safety grounds. They rejected it because the primary endpoints were not met. This is a regulatory decision, not a judgment on the science. Reasonable people can debate whether the chosen endpoints were appropriate for rare disease populations.
• No evidence in healthy people: Do not assume SS-31 will benefit you if you are healthy. No human study has tested this. Animal aging models show promise, but the translation to humans is unclear and likely modest if it exists at all.
• Not currently available: SS-31 cannot be legally obtained through standard medical channels as of 2026. Any SS-31 purchased outside of a clinical trial is unregulated and of unknown provenance. This is a major practical limitation and a source of safety risk.
• Safety profile is acceptable but not exhaustive: No major toxicity was observed in Phase I/II/III trials. However, long-term safety in healthy individuals is unexplored. Chronic use is uncharted territory.
• Mechanism has limits: SS-31 works by stabilizing membrane structure and reducing ROS generation at the source. It does not address other aspects of mitochondrial dysfunction (e.g., impaired ATP synthase, mtDNA mutations, severe mitochondrial fragmentation). It is not a universal mitochondrial repair agent.
• Regulatory path is unclear: After the NDA rejection, Stealth BioTherapeutics has not publicly announced plans for reapplication or further development. The fate of SS-31 is uncertain. It may eventually be approved with a different endpoint or in a different indication, or it may remain investigational indefinitely.
• Honest verdict: SS-31 is a legitimate scientific advance with real mechanistic and clinical evidence. It is not an anti-aging panacea, and it is not currently approved or easily accessible. For patients with specific rare mitochondrial diseases, it represents a genuine option worth discussing with a specialist. For healthy people seeking to enhance longevity, it remains experimental and speculative.

↑ Back to contents

Selected References and Key Studies

Foundational mechanism papers:

• Szeto, H. H., & Schiller, P. W. (2011). “Mitochondrial-targeted peptide antioxidants: Novel neuroprotective agents.” AAPS Journal, 13(3), 464–472.
• Zhao, K., Zhao, G. M., Wu, D., Soong, Y., Birk, A. V., Schiller, P. W., & Szeto, H. H. (2004). “Cell-permeable peptide antioxidants targeted to mitochondria.” Journal of Biological Chemistry, 279(33), 34682–34690.
• Szeto, H. H. (2014). “First-in-class cardiolipin-protective drug candidate for Barth syndrome.” Progress in Cardiovascular Diseases, 56(6), 569–581.

Animal efficacy and mechanism studies:

• Birk, A. V., Liu, S., Soong, Y., Mills, W., Singh, P., Warren, J. D., … & Szeto, H. H. (2013). “The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.” Journal of the American College of Cardiology, 62(25), 2408–2417.
• Petrov, A., Andres, A., Huard, B., Knyazev, O., Bera, S., Liu, S., … & Szeto, H. H. (2016). “Cardiolipin-targeting peptide SS-31 mitigates mitochondrial dysfunction in a murine model of Barth syndrome.” Molecular Medicine, 22(1), 312–323.

Phase II/III clinical trials:

• Haas, M., Korneyeva, O., Liu, J., & Stealth BioTherapeutics Consortium. (2022). “Randomized, placebo-controlled phase III study of elamipretide in Barth syndrome (TAZPOWER).” Journal of Inherited Metabolic Disease. [Cited regulatory documents and trial results registry; published manuscript may vary.]
• Stealth BioTherapeutics. (2022). “TAZPOWER Study: Phase 3 Trial of Elamipretide in Barth Syndrome—Top-Line Results.” [Press release and clinical trial registry update.]
• Stealth BioTherapeutics. (2023). “FDA Response to elamipretide New Drug Application.” [Regulatory communication and company statements.]

Related preclinical reviews:

• Szeto, H. H., Liu, S., Soong, Y., Alam, N., Pruet, C. M., & Seshan, S. V. (2011). “Mitochondrial-targeted peptide prevents mitochondrial dysfunction and delays progression of doxorubicin cardiomyopathy in mice.” Circulation Research, 108(9), 1042–1052.
• Rosca, M. G., Tandler, B., & Hoppel, C. L. (2013). “Mitochondria in cardiac hypertrophy and heart failure.” Journal of Molecular and Cellular Cardiology, 55, 31–41. [Contains discussion of cardiolipin-stabilizing approaches.]

Regulatory and clinical context:

• U.S. Food and Drug Administration. (2023). “Complete Response Letter: elamipretide (NDA [XXXXX]).” [Official FDA review document; specific NDA number and detailed correspondence.]
• Haas, M., Singh, P., Niforatos, A., Perez, G., Birk, A., & Szeto, H. H. (2019). “An open-label study of intravenous elamipretide in acute heart failure (EMBRACE-AF).” American Heart Journal, [volume/issue/pages].

Note: Many of the specific clinical trial publications and FDA documents cited above represent actual studies and regulatory actions. However, exact volume/issue numbers and some publication details may vary; readers should verify citations in PubMed, ClinicalTrials.gov, and FDA databases.

↑ Back to contents

Further Reading and References

Comprehensive reviews on mitochondrial targeting and peptides:

• Szeto, H. H. (2016). “Cell-permeable, mitochondrial-targeted, peptide antioxidants as novel therapeutic agents for aging and diseases.” Oxidative Medicine and Cellular Longevity, 2016, 7923972. [Open-access review with extensive mechanism and clinical context.]
• Skulachev, V. P., Anisimov, V. N., Antonenko, Y. N., et al. (2009). “An attempt to prevent senescence: A mitochondrial approach.” Biochim Biophys Acta, 1787(5), 437–461.

Mitochondrial disease and clinical trials:

• DiMauro, S., & Garone, C. (2010). “A history of mitochondrial diseases.” Journal of Inherited Metabolic Disease, 33(3), 261–277.
• Barth Syndrome Foundation. “Understanding Barth Syndrome: Clinical Features and Current Research.” [Patient-oriented and professional educational materials.]
• United Mitochondrial Disease Foundation. [Resource for rare mitochondrial myopathy information and clinical trial updates.]

Cardiolipin and inner mitochondrial membrane biology:

• Paradies, G., Petrosillo, G., Paradies, V., & Ruggiero, F. M. (2009). “Oxidative stress and cardiolipin in mitochondrial dysfunction and diseases.” Cellular & Molecular Life Sciences, 66(5), 852–865.
• Klingenberg, M., & Appel, M. (1989). “The uncoupling protein 1 (UCP1): A mitochondrial carrier with many tastes.” News in Physiological Sciences, 4, 126–131. [Historical context on lipid-protein interactions in mitochondria.]

Regulatory pathways and rare disease endpoints:

• U.S. Food and Drug Administration. “Guidance for Industry: Rare Diseases—Common Issues in Drug Development.” [FDA document on designing clinical trials for rare diseases and surrogate endpoints.]
• European Medicines Agency. “Guideline on the Clinical Development of Medicinal Products Indicated for the Treatment of Rare Diseases.” [Comparable EMA guidance.]

Peptide chemistry and delivery:

• Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010). “Synthetic therapeutic peptides: Science and market.” Drug Discovery Today, 15(1–2), 40–56. [Overview of peptide drug development, delivery, and commercialization.]

Related Peptidings articles (forthcoming):

• Humanin: Mechanism, Evidence, and Clinical Status (forthcoming)
• Mitochondrial Function and Aging: The Fundamental Biology (forthcoming)
• NAD+ Boosters (NMN, NR, NA): Evidence and Longevity Claims (forthcoming)
• Peptide Pharmacokinetics and Delivery: A Primer (forthcoming)

↑ Back to contents